查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1873692

PD-L1生物標記檢測：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

PD-L1 Biomarker Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 93 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球 PD-L1 生物標記檢測市場預計在 2024 年達到 28.15 億美元，預計到 2031 年將達到 270.2 億美元，在預測期（2025-2031 年）內複合年成長率為 38.7%。

PD-L1生物標記檢測測量癌細胞上PD-L1的含量。 PD-L1是一種蛋白質，它能阻止免疫細胞攻擊體內無害細胞。正常情況下，免疫系統會攻擊病毒和細菌等外來物質，而不會攻擊自身健康的細胞。一些癌細胞具有高水平的PD-L1，這使它們能夠「欺騙」免疫系統，避免被當作外來物攻擊。目前的PD-L1檢測是基於免疫組織化學（IHC）技術，該技術利用抗體檢測組織切片（例如肝臟、胰臟、心臟等）中細胞表面存在的蛋白質（抗原）。 PD-L1是一種配體，它與PD-1（程序性死亡受體-1）結合，PD-1表達於活化的T細胞上，並在腫瘤逃避免疫反應中發揮作用。 PD-L1抑制T細胞的活化和增殖，因此作為癌症治療的重要標靶而備受關注。免疫組織化學 (IHC) 檢測 PD-L1 蛋白被廣泛用作抗 PD-1/PD-L1 療法的預測性生物標記檢測。 PD-L1 檢測用於識別患者是否患有可能受益於免疫療法的癌症。

PD-L1生物標記檢測市場的發展主要得益於免疫查核點抑制劑治療方法的快速擴張，尤其是標靶PD-1/PD-L1軸的療法。這些治療方法在治療多種晚期癌症方面取得了顯著的臨床成功，從而推動了基於PD-L1表達的患者分層以最佳化治療效果的廣泛需求。此外，精準醫療的興起也提升了分子診斷的重要性。臨床醫師和藥物研發人員越來越重視利用PD-L1檢測來指南治療決策，並將其作為輔助診斷手段，尤其是在自動化免疫組化（IHC）系統、新一代定序（NGS）平台和人工智慧（AI）增強型分析技術等診斷技術不斷進步的背景下，PD-L1檢測的重要性日益凸顯。

儘管有這些正面趨勢，但由於通訊協定、檢測克隆、評分系統和臨界值缺乏標準化，PD-L1 檢測目前仍面臨許多挑戰。這種不一致導致結果差異顯著（據報導，不同檢測方法之間的變異性為 19% 至 32%），從而降低了診斷的可靠性，並使臨床決策複雜化。此外，先進檢測技術（如免疫組化、二代定序）的高昂成本和不均衡的報銷制度也造成了經濟障礙，阻礙了其廣泛應用，並加劇了醫療保健方面的不平等，尤其是在發展中地區。

PD-L1生物標記檢測類別包括PD-L1(22C3)、PD-L1(28-8)、PD-L1(SP142)、PD-L1(SP263)等，其中PD-L1(22C3)收入比例%。 PD-L1生物標記檢測廣泛應用於醫院和診斷檢查室。預計到2024年，醫院將佔據PD-L1生物標記檢測的最大佔有率，約佔52.7%。

本報告旨在按地區/國家、類型和應用對全球 PD-L1 生物標記檢測市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

PD-L1生物標記檢測市場規模、估算和預測均以銷售收入為指標，以2024年為基準年，並涵蓋2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定PD-L1生物標記檢測的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Agilent Technologies
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences

按類型分類的細分市場

  • PD-L1（22C3）
  • PD-L1（28-8）
  • PD-L1（SP142）
  • PD-L1（SP263）
  • 其他

應用領域

  • 醫院
  • 診斷中心
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for PD-L1 Biomarker Testing was estimated to be worth US$ 2815 million in 2024 and is forecast to a readjusted size of US$ 27020 million by 2031 with a CAGR of 38.7% during the forecast period 2025-2031.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart). PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti-PD-1/PD-L1 therapies. PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The PD-L1 biomarker testing market is being propelled by the rapid expansion of immune checkpoint inhibitor therapies, particularly those targeting the PD-1/PD-L1 axis, which have shown remarkable clinical success in treating various advanced cancers-spurring widespread demand for stratifying patients based on PD-L1 expression to optimize treatment outcomes. Additionally, the shift toward precision medicine has heightened the importance of molecular diagnostics. Clinicians and pharmaceutical developers are increasingly emphasizing personalized approaches, using PD-L1 testing to guide therapeutic decisions and enable companion diagnostics-especially as diagnostic technologies advance to include automated IHC systems, NGS platforms, and AI-enhanced analysis .

Despite these positive trends, the PD-L1 testing landscape faces significant obstacles due to a lack of standardization across protocols, assay clones, scoring systems, and cut-off thresholds. This inconsistency manifests in discordant results (with variability rates reported between 19-32% across different assays), undermining diagnostic reliability and complicating clinical decision-making. Moreover, high costs associated with advanced testing techniques (IHC, NGS) and uneven reimbursement frameworks create economic barriers, particularly in developing regions, impeding broad accessibility and exacerbating healthcare disparities.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2024 is about 21.68%. PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.

This report aims to provide a comprehensive presentation of the global market for PD-L1 Biomarker Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of PD-L1 Biomarker Testing by region & country, by Type, and by Application.

The PD-L1 Biomarker Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 Biomarker Testing.

Market Segmentation

By Company

  • Agilent Technologies
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences

Segment by Type

  • PD-L1 (22C3)
  • PD-L1(28-8)
  • PD-L1 (SP142)
  • PD-L1 (SP263)
  • Other

Segment by Application

  • Hospital
  • Diagnostic Center
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of PD-L1 Biomarker Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of PD-L1 Biomarker Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of PD-L1 Biomarker Testing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 PD-L1 Biomarker Testing Product Introduction
  • 1.2 Global PD-L1 Biomarker Testing Market Size Forecast (2020-2031)
  • 1.3 PD-L1 Biomarker Testing Market Trends & Drivers
    • 1.3.1 PD-L1 Biomarker Testing Industry Trends
    • 1.3.2 PD-L1 Biomarker Testing Market Drivers & Opportunity
    • 1.3.3 PD-L1 Biomarker Testing Market Challenges
    • 1.3.4 PD-L1 Biomarker Testing Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global PD-L1 Biomarker Testing Players Revenue Ranking (2024)
  • 2.2 Global PD-L1 Biomarker Testing Revenue by Company (2020-2025)
  • 2.3 Key Companies PD-L1 Biomarker Testing Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies PD-L1 Biomarker Testing Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of PD-L1 Biomarker Testing
  • 2.6 PD-L1 Biomarker Testing Market Competitive Analysis
    • 2.6.1 PD-L1 Biomarker Testing Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by PD-L1 Biomarker Testing Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 Biomarker Testing as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 PD-L1 (22C3)
    • 3.1.2 PD-L1(28-8)
    • 3.1.3 PD-L1 (SP142)
    • 3.1.4 PD-L1 (SP263)
    • 3.1.5 Other
  • 3.2 Global PD-L1 Biomarker Testing Sales Value by Type
    • 3.2.1 Global PD-L1 Biomarker Testing Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global PD-L1 Biomarker Testing Sales Value, by Type (2020-2031)
    • 3.2.3 Global PD-L1 Biomarker Testing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Diagnostic Center
    • 4.1.3 Others
  • 4.2 Global PD-L1 Biomarker Testing Sales Value by Application
    • 4.2.1 Global PD-L1 Biomarker Testing Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global PD-L1 Biomarker Testing Sales Value, by Application (2020-2031)
    • 4.2.3 Global PD-L1 Biomarker Testing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global PD-L1 Biomarker Testing Sales Value by Region
    • 5.1.1 Global PD-L1 Biomarker Testing Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global PD-L1 Biomarker Testing Sales Value by Region (2020-2025)
    • 5.1.3 Global PD-L1 Biomarker Testing Sales Value by Region (2026-2031)
    • 5.1.4 Global PD-L1 Biomarker Testing Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 5.2.2 North America PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 5.3.2 Europe PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 5.4.2 Asia Pacific PD-L1 Biomarker Testing Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 5.5.2 South America PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions PD-L1 Biomarker Testing Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions PD-L1 Biomarker Testing Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 6.3.2 United States PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States PD-L1 Biomarker Testing Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 6.4.2 Europe PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe PD-L1 Biomarker Testing Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 6.5.2 China PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China PD-L1 Biomarker Testing Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 6.6.2 Japan PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan PD-L1 Biomarker Testing Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 6.7.2 South Korea PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea PD-L1 Biomarker Testing Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 6.8.2 Southeast Asia PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia PD-L1 Biomarker Testing Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India PD-L1 Biomarker Testing Sales Value, 2020-2031
    • 6.9.2 India PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India PD-L1 Biomarker Testing Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Agilent Technologies
    • 7.1.1 Agilent Technologies Profile
    • 7.1.2 Agilent Technologies Main Business
    • 7.1.3 Agilent Technologies PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.1.4 Agilent Technologies PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Agilent Technologies Recent Developments
  • 7.2 Roche
    • 7.2.1 Roche Profile
    • 7.2.2 Roche Main Business
    • 7.2.3 Roche PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.2.4 Roche PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Roche Recent Developments
  • 7.3 Merck
    • 7.3.1 Merck Profile
    • 7.3.2 Merck Main Business
    • 7.3.3 Merck PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.3.4 Merck PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Merck Recent Developments
  • 7.4 Bristol-Myers Squibb
    • 7.4.1 Bristol-Myers Squibb Profile
    • 7.4.2 Bristol-Myers Squibb Main Business
    • 7.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Bristol-Myers Squibb Recent Developments
  • 7.5 AstraZeneca
    • 7.5.1 AstraZeneca Profile
    • 7.5.2 AstraZeneca Main Business
    • 7.5.3 AstraZeneca PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.5.4 AstraZeneca PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.5.5 AstraZeneca Recent Developments
  • 7.6 Ono Pharmaceutical
    • 7.6.1 Ono Pharmaceutical Profile
    • 7.6.2 Ono Pharmaceutical Main Business
    • 7.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Ono Pharmaceutical Recent Developments
  • 7.7 Regeneron
    • 7.7.1 Regeneron Profile
    • 7.7.2 Regeneron Main Business
    • 7.7.3 Regeneron PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.7.4 Regeneron PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Regeneron Recent Developments
  • 7.8 Innovent
    • 7.8.1 Innovent Profile
    • 7.8.2 Innovent Main Business
    • 7.8.3 Innovent PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.8.4 Innovent PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Innovent Recent Developments
  • 7.9 Hengrui Medicine
    • 7.9.1 Hengrui Medicine Profile
    • 7.9.2 Hengrui Medicine Main Business
    • 7.9.3 Hengrui Medicine PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.9.4 Hengrui Medicine PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Hengrui Medicine Recent Developments
  • 7.10 Junshi Biosciences
    • 7.10.1 Junshi Biosciences Profile
    • 7.10.2 Junshi Biosciences Main Business
    • 7.10.3 Junshi Biosciences PD-L1 Biomarker Testing Products, Services and Solutions
    • 7.10.4 Junshi Biosciences PD-L1 Biomarker Testing Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Junshi Biosciences Recent Developments

8 Industry Chain Analysis

  • 8.1 PD-L1 Biomarker Testing Industrial Chain
  • 8.2 PD-L1 Biomarker Testing Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 PD-L1 Biomarker Testing Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 PD-L1 Biomarker Testing Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. PD-L1 Biomarker Testing Market Trends
  • Table 2. PD-L1 Biomarker Testing Market Drivers & Opportunity
  • Table 3. PD-L1 Biomarker Testing Market Challenges
  • Table 4. PD-L1 Biomarker Testing Market Restraints
  • Table 5. Global PD-L1 Biomarker Testing Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global PD-L1 Biomarker Testing Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies PD-L1 Biomarker Testing Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies PD-L1 Biomarker Testing Product Type
  • Table 9. Key Companies Time to Begin Mass Production of PD-L1 Biomarker Testing
  • Table 10. Global PD-L1 Biomarker Testing Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 Biomarker Testing as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global PD-L1 Biomarker Testing Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global PD-L1 Biomarker Testing Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global PD-L1 Biomarker Testing Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global PD-L1 Biomarker Testing Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global PD-L1 Biomarker Testing Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global PD-L1 Biomarker Testing Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global PD-L1 Biomarker Testing Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global PD-L1 Biomarker Testing Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global PD-L1 Biomarker Testing Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global PD-L1 Biomarker Testing Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global PD-L1 Biomarker Testing Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global PD-L1 Biomarker Testing Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global PD-L1 Biomarker Testing Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global PD-L1 Biomarker Testing Sales Value by Region (2020-2025) & (%)
  • Table 27. Global PD-L1 Biomarker Testing Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions PD-L1 Biomarker Testing Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions PD-L1 Biomarker Testing Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions PD-L1 Biomarker Testing Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Agilent Technologies Basic Information List
  • Table 32. Agilent Technologies Description and Business Overview
  • Table 33. Agilent Technologies PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Agilent Technologies (2020-2025)
  • Table 35. Agilent Technologies Recent Developments
  • Table 36. Roche Basic Information List
  • Table 37. Roche Description and Business Overview
  • Table 38. Roche PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Roche (2020-2025)
  • Table 40. Roche Recent Developments
  • Table 41. Merck Basic Information List
  • Table 42. Merck Description and Business Overview
  • Table 43. Merck PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Merck (2020-2025)
  • Table 45. Merck Recent Developments
  • Table 46. Bristol-Myers Squibb Basic Information List
  • Table 47. Bristol-Myers Squibb Description and Business Overview
  • Table 48. Bristol-Myers Squibb PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Bristol-Myers Squibb (2020-2025)
  • Table 50. Bristol-Myers Squibb Recent Developments
  • Table 51. AstraZeneca Basic Information List
  • Table 52. AstraZeneca Description and Business Overview
  • Table 53. AstraZeneca PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of AstraZeneca (2020-2025)
  • Table 55. AstraZeneca Recent Developments
  • Table 56. Ono Pharmaceutical Basic Information List
  • Table 57. Ono Pharmaceutical Description and Business Overview
  • Table 58. Ono Pharmaceutical PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Ono Pharmaceutical (2020-2025)
  • Table 60. Ono Pharmaceutical Recent Developments
  • Table 61. Regeneron Basic Information List
  • Table 62. Regeneron Description and Business Overview
  • Table 63. Regeneron PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Regeneron (2020-2025)
  • Table 65. Regeneron Recent Developments
  • Table 66. Innovent Basic Information List
  • Table 67. Innovent Description and Business Overview
  • Table 68. Innovent PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Innovent (2020-2025)
  • Table 70. Innovent Recent Developments
  • Table 71. Hengrui Medicine Basic Information List
  • Table 72. Hengrui Medicine Description and Business Overview
  • Table 73. Hengrui Medicine PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Hengrui Medicine (2020-2025)
  • Table 75. Hengrui Medicine Recent Developments
  • Table 76. Junshi Biosciences Basic Information List
  • Table 77. Junshi Biosciences Description and Business Overview
  • Table 78. Junshi Biosciences PD-L1 Biomarker Testing Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in PD-L1 Biomarker Testing Business of Junshi Biosciences (2020-2025)
  • Table 80. Junshi Biosciences Recent Developments
  • Table 81. Key Raw Materials Lists
  • Table 82. Raw Materials Key Suppliers Lists
  • Table 83. PD-L1 Biomarker Testing Downstream Customers
  • Table 84. PD-L1 Biomarker Testing Distributors List
  • Table 85. Research Programs/Design for This Report
  • Table 86. Key Data Information from Secondary Sources
  • Table 87. Key Data Information from Primary Sources

List of Figures

  • Figure 1. PD-L1 Biomarker Testing Product Picture
  • Figure 2. Global PD-L1 Biomarker Testing Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global PD-L1 Biomarker Testing Sales Value (2020-2031) & (US$ Million)
  • Figure 4. PD-L1 Biomarker Testing Report Years Considered
  • Figure 5. Global PD-L1 Biomarker Testing Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by PD-L1 Biomarker Testing Revenue in 2024
  • Figure 7. PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. PD-L1 (22C3) Picture
  • Figure 9. PD-L1(28-8) Picture
  • Figure 10. PD-L1 (SP142) Picture
  • Figure 11. PD-L1 (SP263) Picture
  • Figure 12. Other Picture
  • Figure 13. Global PD-L1 Biomarker Testing Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global PD-L1 Biomarker Testing Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Product Picture of Hospital
  • Figure 16. Product Picture of Diagnostic Center
  • Figure 17. Product Picture of Others
  • Figure 18. Global PD-L1 Biomarker Testing Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 19. Global PD-L1 Biomarker Testing Sales Value Market Share by Application, 2024 & 2031
  • Figure 20. North America PD-L1 Biomarker Testing Sales Value (2020-2031) & (US$ Million)
  • Figure 21. North America PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Europe PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Europe PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Asia Pacific PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Asia Pacific PD-L1 Biomarker Testing Sales Value by Region (%), 2024 VS 2031
  • Figure 26. South America PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. South America PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Middle East & Africa PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Middle East & Africa PD-L1 Biomarker Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Key Countries/Regions PD-L1 Biomarker Testing Sales Value (%), (2020-2031)
  • Figure 31. United States PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. United States PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 33. United States PD-L1 Biomarker Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 34. Europe PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 36. Europe PD-L1 Biomarker Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 37. China PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. China PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 39. China PD-L1 Biomarker Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Japan PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Japan PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Japan PD-L1 Biomarker Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 43. South Korea PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South Korea PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 45. South Korea PD-L1 Biomarker Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Southeast Asia PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Southeast Asia PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Southeast Asia PD-L1 Biomarker Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 49. India PD-L1 Biomarker Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. India PD-L1 Biomarker Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 51. India PD-L1 Biomarker Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 52. PD-L1 Biomarker Testing Industrial Chain
  • Figure 53. PD-L1 Biomarker Testing Manufacturing Cost Structure
  • Figure 54. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed